Clinical Trials Logo

Respiration Disorders clinical trials

View clinical trials related to Respiration Disorders.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06405451 Enrolling by invitation - Multiple Sclerosis Clinical Trials

Respiratory Muscle Training Program in Patients With Multiple Sclerosis

Start date: January 10, 2024
Phase: N/A
Study type: Interventional

This is a quasi-experimental pre-post trial aimed at investigating the effects of respiratory muscle training (RMT) as trunk stabilization exercise in patients diagnosed with multiple sclerosis (MS)

NCT ID: NCT06011356 Enrolling by invitation - Diabetes Clinical Trials

Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study

SWIPER-MOVES
Start date: August 30, 2023
Phase:
Study type: Observational

Aims of the study: 1. To deliver a scalable wellbeing programme to the local population of Imperial College Healthcare NHS Trust, focusing on movement. 2. To describe the natural history of long-term conditions using digital data from a smartwatch. 3. To identify digital information that is routinely collected by a smart watch that can be used to predict outcomes in patients with long term conditions. 4. To identify factors that determine whether participants engage with and improve in a movement programme. Adult patients who are registered to the Imperial NHS Care Information Exchange (CIE), an NHS patient-facing electronic health record, are eligible to participate in the study. Participants will receive a smart watch for self-monitoring of their movement and wellbeing and be asked to wear the device as much as possible. They will be asked to download a smartphone application called Connected Life, which displays movement and information on heart rate, breathing and oxygen levels to both the participant and the research team (digital data). Participants will receive secure login details for the Connected Life application from the research team, to ensure data privacy. The research team will look at participants' health records, and attempt to identify associations between the digital data and clinical information. This will allow the research team to identify digital data that predicts the onset and natural history of long term conditions, which may potentially allow for earlier diagnosis for future patients. The primary outcome of the study is the identification of trends in movement based on step-count data recorded by the smartwatch.

NCT ID: NCT05962645 Enrolling by invitation - Healthy Clinical Trials

Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

Vapendavir (VPV) is potent virostatic antiviral agent active against all known enterovirus species. VPV binds to the viral capsid, thereby inhibiting viral attachment to the target cell and, independently, preventing release of viral RNA (ribonucleic acid) into the cell. Alt VPV-101 is meant to investigate vapendavir in patients with chronic obstructive pulmonary disease (COPD) who develop a rhinoviral infection. This is a Phase 1, open-label, unblinded study. The primary objective of this study is to characterize single and multiple dose (plus a loading dose) plasma PK profiles of VPV in healthy participants (Group A) and participants with COPD (Group B). Group A is an open-label, 2-sequence, and up to a 3-period, cross-over study to assess the single-dose PK parameters and safety of VPV. Healthy participants may opt to participate in only the first 2 periods, all 3 periods or BID dosing, but it is preferred that participants complete all 3 periods. Group B is an open-label, multi-dose investigation of VPV PK parameters and safety in participants with COPD. Post-dose, follow up will continue for a minimum of 14 days and a maximum of 30 days, depending on which Group the participant is in and which periods said participant completes. There is a target for up to 24 adult participants comprised of healthy participants and participants with COPD.

NCT ID: NCT05727852 Enrolling by invitation - Cystic Fibrosis Clinical Trials

Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases

Start date: January 30, 2023
Phase:
Study type: Observational

Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory diseases with age and gender-matched healthy adults in order to identify a disease-specific exhaled eVOCs profiles and markers of respiratory and cardiovascular disorders.

NCT ID: NCT05724082 Enrolling by invitation - Pneumonia Clinical Trials

The Effect of Household Air Pollution on Lung Function Growth in Infants With Pneumonia in Sub-Saharan Africa

PLUS2
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the feasibility and acceptability of a household-based clean air intervention

NCT ID: NCT05692362 Enrolling by invitation - Respiratory Disease Clinical Trials

Measure Airway Compliance by Endobronchial Optical Coherence Tomography

Start date: March 1, 2023
Phase:
Study type: Observational

Optical Coherence Tomography (OCT)is a novel, non-invasive, high resolution special optical imaging techniques. In airway, Measure airway area and airway wall thickness is the most usage of Endobronchial Optical Coherence Tomography (EB-OCT). Recently, the new protocol of EB-OCT is used to measure airway compliance, We will establish a new methodology of EB-OCT for measuring airway compliance, which will provide a new means to study respiratory diseases.

NCT ID: NCT05592769 Enrolling by invitation - Respiratory Disease Clinical Trials

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device

Start date: November 10, 2022
Phase: N/A
Study type: Interventional

This goal of this study is to assess the suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) device for patients on injectable medications in the home-setting, for the management of respiratory disorders. The HealthBeacon ICMS is composed of the Smart Sharps Bin, Companion App and Care Team support. The Smart Sharps Bin a digitally connected sharps container and is pre-programmed with a patient's injection schedule. It creates a time-stamped record of each used injection deposited into it to calculate a patients' adherence to treatment. Following disposal, the next date of injection and rotating injection site is updated without requiring any extra work on behalf of the patient. The system also proactively supports enhanced compliance through a series of smart dose reminders and intervention calls, to help patients stay on track. Clinical teams can then review patient adherence data remotely via an online platform. The main aims of this study include the following: - To demonstrate the suitability of the HealthBeacon ICMS as an RTM device for respiratory patients through successful billing and reimbursement for physicians - To provide data to support the reimbursement of the HealthBeacon ICMS by Private Payors in the future Participants prescribed injectable medication for the treatment of a diagnosed respiratory condition will be enrolled by the Principal Investigator (PI) and referred to HealthBeacon. Participants will then be provided with access to the HealthBeacon ICMS to remotely track and support their adherence to treatment in the home-setting. Participants will use the system for 6 months and their adherence data during this time will be collected, which the PI and clinical team involved will be able to remotely access and review. At various stages of the study, the applicable RTM codes will be billed for, for each participant. These stages include when providing each participant with access to the HealthBeacon system, including the Smart Sharps Bin, when providing each participant with education on how to use the device, and when the clinical team monitors each individual patients' adherence data collected by the HealthBeacon system on a monthly basis.

NCT ID: NCT05322785 Enrolling by invitation - Healthy Clinical Trials

Optimization of Exhaled Biomarker Collection and Analysis

EBC
Start date: February 2, 2020
Phase: N/A
Study type: Interventional

This is an exploratory study designed to optimize, standardize, and validate novel breath biomarkers; there are no objective endpoints. The goal of this study is to generate pilot data to be used to generate hypothesis-driven studies.

NCT ID: NCT05162703 Enrolling by invitation - Clinical trials for Pediatric Respiratory Diseases

Evaluation of Exercise Induced Bronchoconstriction Using a Novel Automated Digital Clinical Decision System

Start date: September 27, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess if the unstandardized field exercise challenge test (ECT) using AsthmaTuner can be performed independently by youths that have been investigated for asthma. This is an open feasibility study including youths who have been investigated for asthma. Participants will be equipped with a digital spirometer and mobile phone app to perform an exercise tests in their natural training environment. Feasibility will be evaluated using questionnaires.

NCT ID: NCT04880551 Enrolling by invitation - COPD Clinical Trials

Ventilation Imbalances in Mild to Moderate Chronic Obstructive Pulmonary Disease

VAPOR
Start date: June 30, 2021
Phase:
Study type: Observational

The Investigators plan a single center study to get preliminary data to answer a number of fundamental questions directly related to management of COPD. The research will determine whether ventilation heterogeneity and distribution of ventilation inform, determine, assist or drive the: 1) status or clinical course in patients with COPD, 2) understanding of factors associated with activities of daily living and quality of life in patients , 3) risk of exacerbation or hospitalization in those with COPD, and 4) predictors of therapeutic pathway or treatment regime.